Matches in Wikidata for { <http://www.wikidata.org/entity/Q82777810> ?p ?o ?g. }
Showing items 1 to 52 of
52
with 100 items per page.
- Q82777810 description "artículu científicu espublizáu n'abril de 2010" @default.
- Q82777810 description "im April 2010 veröffentlichter wissenschaftlicher Artikel" @default.
- Q82777810 description "scientific article published on 01 April 2010" @default.
- Q82777810 description "wetenschappelijk artikel" @default.
- Q82777810 description "наукова стаття, опублікована у квітні 2010" @default.
- Q82777810 name "Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study" @default.
- Q82777810 name "Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study" @default.
- Q82777810 type Item @default.
- Q82777810 label "Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study" @default.
- Q82777810 label "Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study" @default.
- Q82777810 prefLabel "Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study" @default.
- Q82777810 prefLabel "Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study" @default.
- Q82777810 P1433 Q82777810-CE8F0787-F45C-40B1-9FA8-1BDE76AF6F0B @default.
- Q82777810 P1476 Q82777810-A5BD517C-FD4A-426F-A4AE-2811C3FEE7FA @default.
- Q82777810 P2093 Q82777810-04DE6410-654E-45C8-9B1F-605F7C31F1A2 @default.
- Q82777810 P2093 Q82777810-095AD48D-DB8E-4F21-80F9-0E481B41F5DA @default.
- Q82777810 P2093 Q82777810-0BE1DDD8-733C-4308-A671-6BA1BFD9CA83 @default.
- Q82777810 P2093 Q82777810-59B3D7C5-5F74-4003-BCC0-1DDBF4E71625 @default.
- Q82777810 P2093 Q82777810-6A571569-1C8D-448E-973B-4A42D878A711 @default.
- Q82777810 P2093 Q82777810-99C92C90-2B6B-404C-97C4-5ADA06C52565 @default.
- Q82777810 P2093 Q82777810-9D1406F6-CA29-40E9-BD00-3F5389131984 @default.
- Q82777810 P2093 Q82777810-C204FF6C-BF75-4833-A5F8-69F4DCDE772E @default.
- Q82777810 P304 Q82777810-9ABF09A1-035C-447B-96CA-40EF71D0412B @default.
- Q82777810 P31 Q82777810-61ED22A2-0ACB-4332-961B-63260F42F185 @default.
- Q82777810 P356 Q82777810-70722F4C-5ED7-4D9F-B900-B78A707F2A75 @default.
- Q82777810 P433 Q82777810-82BAA8DD-2F03-416F-ACE0-88B2B645B37E @default.
- Q82777810 P478 Q82777810-860899A8-5964-471A-87B2-538F43BBA6E0 @default.
- Q82777810 P577 Q82777810-50790E6D-9979-4729-94D7-9F5B23C99F66 @default.
- Q82777810 P698 Q82777810-FDE67432-64F3-457E-8E2D-C134FA2CA407 @default.
- Q82777810 P921 Q82777810-391FEC1C-5C4A-4A46-B2B4-1439073EB57C @default.
- Q82777810 P921 Q82777810-9D183554-D9BC-4C7A-AA6E-982EE298B462 @default.
- Q82777810 P356 ART.27348 @default.
- Q82777810 P698 20131276 @default.
- Q82777810 P1433 Q23929027 @default.
- Q82777810 P1476 "Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study" @default.
- Q82777810 P2093 "Alan Mendelsohn" @default.
- Q82777810 P2093 "Christopher Ritchlin" @default.
- Q82777810 P2093 "Daniel Baker" @default.
- Q82777810 P2093 "Joel Kremer" @default.
- Q82777810 P2093 "John Han" @default.
- Q82777810 P2093 "Lilianne Kim" @default.
- Q82777810 P2093 "Peter Taylor" @default.
- Q82777810 P2093 "Zhenhua Xu" @default.
- Q82777810 P304 "917-928" @default.
- Q82777810 P31 Q13442814 @default.
- Q82777810 P356 "10.1002/ART.27348" @default.
- Q82777810 P433 "4" @default.
- Q82777810 P478 "62" @default.
- Q82777810 P577 "2010-04-01T00:00:00Z" @default.
- Q82777810 P698 "20131276" @default.
- Q82777810 P921 Q187255 @default.
- Q82777810 P921 Q269829 @default.